TREA

79209028 - MULTIBODY

Follow

Information

  • Trademark
  • 79209028
  • Serial Number
    79209028
  • Registration Number
    5450600
  • Filing Date
    October 21, 2016
    8 years ago
  • Registration Date
    April 24, 2018
    6 years ago
  • Transaction Date
    December 03, 2024
    a month ago
  • Status Date
    November 08, 2024
    2 months ago
  • Published for Opposition Date
    February 06, 2018
    6 years ago
  • Location Date
    April 24, 2018
    6 years ago
  • Status Code
    709
  • Current Location
    PUBLICATION AND ISSUE SECTION
    Employee Name
    JACKSON, STEVEN
  • Attorney Docket Number
    17337.27USIB
    Attorney Name
    Christopher J. Schulte
    Law Office Assigned Location Code
    L70
  • Owners
Information
Mark Drawing Code
4
Mark Identification
MULTIBODY
Case File Statements
  • GS0401: Treatment and transformation of materials, namely, custom manufacture of chemicals, biologicals, antibodies and antibody fragments; contract manufacturing in the field of chemicals, biologicals, antibodies and antibody fragments; services for the custom manufacture of therapies using antibodies and antibody fragments
  • GS0051: Pharmaceutical preparations for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases; veterinary preparations for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases; therapeutic preparations in the nature of antibodies and antibody fragments for medical and veterinary purposes; antibodies, being pharmaceutical preparations for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases; antibody fragments being pharmaceutical preparations for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases; monoclonal antibodies for therapeutic purposes, namely, therapeutic agents for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases; antibodies and antibody fragments, being pharmaceutical preparations for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases, for medical and veterinary diagnostics; antibodies and antibody fragments, being pharmaceutical preparations for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases, for use in the discovery, preclinical and clinical development of therapeutic products; antibodies and antibody fragments, being pharmaceutical preparations for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases, for use in the manufacture of therapeutic products
  • PM0001: MULTI BODY
  • GS0011: Chemicals used in industry and science; chemicals for laboratory research purposes; monoclonal antibodies and antibody fragments for scientific and laboratory use; monoclonal antibodies and antibody fragments for scientific research purposes; monoclonal antibody reagents for scientific and laboratory use; monoclonal antibodies and antibody fragments for scientific research purposes for use in the manufacture of therapeutic products
  • GS0421: Scientific and technological services, namely, scientific research, analysis and testing and research and design in the field of chemicals, biologicals, antibodies and antibody fragments; scientific laboratory services relating to antibodies and antibody fragments; research and development in the field of antibodies and antibody fragments; medical research laboratory services relating to antibodies and antibody fragments; engineering of antibodies and antibody fragments; scientific research relating to the discovery, preclinical and clinical development of therapeutic products; consultancy services relating thereto, namely, consulting in the field of antibody and antibody fragment design
Case File Event Statements
  • 6/1/2017 - 7 years ago
    1 - SN ASSIGNED FOR SECT 66A APPL FROM IB Type: REPR
  • 6/9/2017 - 7 years ago
    4 - APPLICATION FILING RECEIPT MAILED Type: MAFR
  • 6/22/2017 - 7 years ago
    7 - REFUSAL PROCESSED BY MPU Type: RFRR
  • 6/23/2017 - 7 years ago
    8 - NON-FINAL ACTION MAILED - REFUSAL SENT TO IB Type: RFCS
  • 12/7/2017 - 7 years ago
    10 - NEW REPRESENTATIVE AT IB RECEIVED Type: NREP
  • 12/12/2017 - 7 years ago
    11 - TEAS RESPONSE TO OFFICE ACTION RECEIVED Type: TROA
  • 6/5/2017 - 7 years ago
    2 - NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Type: NWOS
  • 6/6/2017 - 7 years ago
    3 - ASSIGNED TO EXAMINER Type: DOCK
  • 6/13/2017 - 7 years ago
    5 - NON-FINAL ACTION WRITTEN Type: CNRT
  • 6/14/2017 - 7 years ago
    6 - NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW Type: RFCR
  • 7/14/2017 - 7 years ago
    9 - REFUSAL PROCESSED BY IB Type: RFNT
  • 12/19/2017 - 7 years ago
    12 - ASSIGNED TO LIE Type: ALIE
  • 12/21/2017 - 7 years ago
    13 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA
  • 12/21/2017 - 7 years ago
    14 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME
  • 12/28/2017 - 7 years ago
    15 - APPROVED FOR PUB - PRINCIPAL REGISTER Type: CNSA
  • 1/17/2018 - 6 years ago
    16 - NOTICE OF PUBLICATION Type: NPUB
  • 2/1/2018 - 6 years ago
    18 - ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED Type: ARAA
  • 2/6/2018 - 6 years ago
    19 - PUBLISHED FOR OPPOSITION Type: PUBO
  • 4/24/2018 - 6 years ago
    20 - REGISTERED-PRINCIPAL REGISTER Type: R.PR
  • 7/24/2018 - 6 years ago
    21 - FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB Type: FICR
  • 2/1/2018 - 6 years ago
    17 - TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED Type: REAP
  • 9/7/2018 - 6 years ago
    24 - FINAL DECISION TRANSACTION PROCESSED BY IB Type: FINO
  • 4/24/2023 - a year ago
    25 - COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED Type: REM3
  • 10/27/2023 - a year ago
    27 - LIMITATION FROM THE IB EXAMINED, NO ACTION IS NEEDED Type: LIMN
  • 11/8/2024 - 2 months ago
    28 - RESTRICTION OF HOLDER'S RIGHT OF DISPOSAL RECEIVED Type: RHRD
  • 11/8/2024 - 2 months ago
    29 - CANCELLED SECTION 71 Type: C71T
  • 8/19/2023 - a year ago
    26 - RESTRICTION OF HOLDER'S RIGHT OF DISPOSAL RECEIVED Type: RHRD
  • 8/9/2018 - 6 years ago
    22 - FINAL DISPOSITION PROCESSED Type: FIMP
  • 8/9/2018 - 6 years ago
    23 - FINAL DISPOSITION NOTICE SENT TO IB Type: FICS